EUVIMEDEUVIMED entdecken
Crossref

Improving Cancer Therapy: The Strong Synergy of Ginsenosides and Chemotherapy

Babu Santha Aswani, Bethsebie Lalduhsaki Sailo, Young Yun Jung, Sosmitha Girisa, Mangala Hegde, Mohammed S Alqahtani, Mohamed Abbas, Hassan Ali Almubarak, Anupam Bishayee, Kwang Seok Ahn, Ajaikumar B. Kunnumakkara

BIOCELL · 2026 · 50 (8) · 1-10

DOI: 10.32604/biocell.2026.073397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BIOCELL, 2026. Verfasst von Babu Santha Aswani und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

: Despite the advancements achieved in chemotherapy, cancer continues to remain a formidable and lethal global threat, ranking as the second leading cause of death worldwide. The development of chemoresistance poses a significant hurdle in cancer treatment. Nonetheless, a therapeutic strategy known as chemosensitization has emerged to counteract cancer cell resistance, wherein the efficacy of one drug is augmented by another. Accumulating evidence suggests that natural products have attracted considerable attention in the cancer therapeutic realm due to their ability to combat multidrug resistance with minimal side effects. Ginsenosides, triterpene saponins extracted from Panax ginseng , have demonstrated significant anticancer activity while exhibiting relatively low toxicity and reduced adverse effects. Co-administration of ginsenosides with chemotherapeutic drugs has been shown to trigger apoptosis, as evidenced by an increased Bcl-2-associated X protein (Bax)/B-cell lymphoma 2 (Bcl-2) ratio, inhibit angiogenesis through suppression of vascular endothelial growth factor (VEGF); and hinder replicative immortality by downregulating stemness-associated markers such as octamer-binding transcription factor 4 (Oct4), Nanog, and sex determining region Y-box 2 (SOX2) in various cancers. Additionally, ginsenosides modulate key chemoresistance pathways, including nuclear factor-kappa B (NF-κ B), signal transducers and activators of transcription (STAT), and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt), as well as their downstream targets, thereby rendering cancer cells more susceptible to chemotherapy. Notably, ginsenosides have been shown to modulate the tumor microenvironment and mitigate the side effects associated with chemotherapeutic drugs. This review aims to consolidate findings from preclinical and clinical studies to elucidate the role of ginsenosides as effective chemosensitizing agents.

Zitieren

APA

Aswani, B. S., Sailo, B. L., Jung, Y. Y., Girisa, S., Hegde, M., Alqahtani, M. S., Abbas, M., Almubarak, H. A., Bishayee, A., Ahn, K. S., & Kunnumakkara, A. B. (2026). Improving Cancer Therapy: The Strong Synergy of Ginsenosides and Chemotherapy. BIOCELL, 50(8), 1-10. https://doi.org/10.32604/biocell.2026.073397

Vancouver

Aswani BS, Sailo BL, Jung YY, Girisa S, Hegde M, Alqahtani MS, et al. Improving Cancer Therapy: The Strong Synergy of Ginsenosides and Chemotherapy. BIOCELL. 2026;50(8):1-10. doi:10.32604/biocell.2026.073397

BibTeX
@article{Aswani2026,
  author = {Aswani, Babu Santha and Sailo, Bethsebie Lalduhsaki and Jung, Young Yun and Girisa, Sosmitha and Hegde, Mangala and Alqahtani, Mohammed S and Abbas, Mohamed and Almubarak, Hassan Ali and Bishayee, Anupam and Ahn, Kwang Seok and Kunnumakkara, Ajaikumar B.},
  title = {Improving Cancer Therapy: The Strong Synergy of Ginsenosides and Chemotherapy},
  journal = {BIOCELL},
  year = {2026},
  volume = {50},
  number = {8},
  pages = {1--10},
  doi = {10.32604/biocell.2026.073397}
}
Kostenlos starten →